A Novel Mutation Diagnosing in Allan–Herndon–Dudley's Syndrome

Abstract

Allan–Herndon–Dudley's syndrome (AHDS) is a rare X-linked recessive disease that causes abnormal serum thyroid function tests, severe hypotonia, intellectual disability, and motor deficit due to a mutation in the monocarboxylate transporter 8, which is a thyroid hormone transporter. A 6-month-old male patient presented to our outpatient clinic with a serious hypotonia complaint. With a preliminary diagnosis of AHDS, a molecular genetic examination was performed. The molecular genetic analysis detected a new previously unidentified variant in the SLC16A2 gene. This case has been presented to report the AHDS, which is a rare cause of hypotonia in patients presenting/consulting with severe hypotonia, global developmental delay, and abnormal thyroid function test results. Besides, a novel pathogenic mutation in the SLC16A2 gene has been described in the present article.

Keywords

fT3 level - hypotonia - mental retardation - SLC16A2

Publication History

Received: 01 April 2021

Accepted: 31 October 2021

Article published online:
13 December 2021

• References

• 1 Allan W, Herndon CN, Dudley FC. Some examples of the inheritance of mental deficiency: apparently sex-linked iodicy and microcephaly. Am J Ment Defic 1944; 48: 325-333
• 2 Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278 (41) 40128-40135
• 3 Heuer H, Visser TJ. Minireview: pathophysiological importance of thyroid hormone transporters. Endocrinology 2009; 150 (03) 1078-1083
• 4 Schwartz CE, May MM, Carpenter NJ. et al. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet 2005; 77 (01) 41-53
• 5 Filho HC, Marui S, Manna TD. et al. Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities. Arq Bras Endocrinol Metabol 2011; 55 (01) 60-66
• 6 Varsome. A clinical-grade Platform for Interpretation of NGS Data. Available at: https://varsome.com/variant/hg19/SLC16A2%20c.1262G%3EC. (accessed on 17.02.2021)
• 7 Friesema EC, Grueters A, Biebermann H. et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004; 364 (9443): 1435-1437
• 8 Remerand G, Boespflug-Tanguy O, Tonduti D. et al; RMLX/AHDS Study Group. Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations. Dev Med Child Neurol 2019; 61 (12) 1439-1447
• 9 Wang J, Zhang Q, Bao X, Chen Y, Yu S. Clinical and genetic features of five patients with Allan-Herndon-Dudley syndrome [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2018; 35 (04) 484-488
• 10 Schwartz CE, Stevenson RE. The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome. Best Pract Res Clin Endocrinol Metab 2007; 21 (02) 307-321
• 11 Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001; 22 (04) 451-476
• 12 Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004; 74 (01) 168-175